Valuation: Syndax Pharmaceuticals, Inc.

Market Cap 1.57B 1.37B 1.3B 1.18B 2.2B 151B 2.21B 15.52B 5.99B 76.76B 5.91B 5.78B 247B P/E 2026 *
-8.73x
P/E 2027 * -21.6x
Enterprise Value 1.93B 1.68B 1.59B 1.44B 2.7B 185B 2.71B 19.02B 7.34B 94.06B 7.24B 7.08B 303B EV / Sales 2026 *
6.1x
EV / Sales 2027 * 4.17x
Free-Float
98.31%
Yield 2026 *
-
Yield 2027 * -
1 day-0.34%
1 week-3.08%
Current month-8.66%
1 month-11.52%
3 months-7.26%
6 months-25.50%
Current year-16.14%
1 week 17.25
Extreme 17.25
18.68
1 month 17.25
Extreme 17.25
21
Current year 16.66
Extreme 16.66
25.59
1 year 12.99
Extreme 12.99
25.59
3 years 8.58
Extreme 8.58
25.59
5 years 8.58
Extreme 8.58
29.86
10 years 3.39
Extreme 3.39
29.86
Manager TitleAgeSince
Chief Executive Officer 55 2022-02-02
Chief Tech/Sci/R&D Officer 57 2013-10-31
Director of Finance/CFO 55 2022-06-12
Director TitleAgeSince
Chairman 68 2008-11-30
Director/Board Member 55 2019-07-03
Director/Board Member 65 2017-01-03
Date Insider Type Main position Quantity % Market Cap. Importance
7/8/26 Exercice

Chief Executive Officer

97,125 0.1096%
6/1/26 Sell

Chief Financial Officer

-1,177 0.0013%
6/1/26 Sell

Chief Executive Officer

-6,847 0.0077%
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-3.08%+14.05%+3.28% 1.58B
+0.11%+2.71%+0.33%+28.59% 46.18B
-1.12%+1.78%+40.07%+27.26% 44.35B
-3.04%-6.29%+322.27%+517.36% 42.21B
-0.74%+1.25%+2.32%+67.94% 40.19B
-0.50%+0.67%+11.79%+40.51% 29.83B
-0.46%+4.22%+21.99%+124.21% 17.17B
-0.97%-10.17% - - 15.7B
-0.57%+8.12%+22.15%+38.93% 15.32B
-3.14%+31.91%-10.60% - 14.5B
Average -0.93%+3.82%+47.15%+106.01% 26.7B
Weighted average by Cap. -1.02%+2.71%+65.36%+131.07%

Financials

2026 *2027 *
Net sales 316M 276M 260M 236M 443M 30.33B 445M 3.12B 1.2B 15.42B 1.19B 1.16B 49.62B 463M 404M 381M 346M 649M 44.43B 651M 4.57B 1.76B 22.59B 1.74B 1.7B 72.69B
Net income -180M -157M -148M -134M -252M -17.24B -253M -1.77B -684M -8.76B -675M -660M -28.2B -74.84M -65.26M -61.62M -55.96M -105M -7.18B -105M -738M -285M -3.65B -281M -275M -11.75B
Net Debt 355M 309M 292M 265M 497M 34.03B 499M 3.5B 1.35B 17.3B 1.33B 1.3B 55.67B 356M 310M 293M 266M 498M 34.13B 500M 3.51B 1.35B 17.35B 1.34B 1.31B 55.83B
Logo Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Employees
298
Date Price Change Volume
26-09-18 US$17.62 -0.34% 5,180,951
26-09-17 US$17.68 +2.31% 2,582,131
26-09-16 US$17.28 -4.48% 2,332,306
26-09-15 US$18.09 -1.42% 1,128,103
26-09-14 US$18.35 +0.94% 1,186,873
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
17.62USD
Average target price
37.55USD
Spread / Average Target
+113.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SNDX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!